Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ubiquitin C-terminal Hydrolase-L5 (
UCH-L5
/UCH37), a member of the deubiquitinases (DUBs), suppresses protein degeneration via removing ubiquitin from the distal subunit of the polyubiquitin chain. The activity of
UCH-L5
is enhanced when
UCH-L5
combines with proteasome 19S regulatory subunit by Rpn13/Admr1 receptor and inhibited when
UCH-L5
interacts with NFRKB. But the role of
UCH-L5
in gliomas remains unknown. In this study, analysis of 19 frozen and 51 paraffin-embedded clinic pathological cases showed that
UCH-L5
expression in
glioma
tissues was lower than normal brain tissues.
In vitro
, we found that
UCH-L5
could inhibit migration and invasion of U87MG and U251 cells. It has been reported that the expression of SNRPN, SNRPF, and CKLF was abnormal in gliomas or other tumors. We also found that SNRPF-siRNA, SNRPN-siRNA and CKLF-siRNA could inhibit migration and invasion of U87MG cells. And knockdown of
UCH-L5
expression improved both mRNA expression and protein level of SNRPF. The relationship between
UCH-L5
and SNRPF was further confirmed in 293T cells. Our study showed that
UCH-L5
could inhibit migration and invasion of
glioma
cells via down regulating expression of SNRPF. And the above findings suggest that
UCH-L5
may inhibit occurrence and metastasis of gliomas.
...
PMID:Ubiquitin carboxyl-terminal hydrolase isozyme L5 inhibits human glioma cell migration and invasion via downregulating SNRPF. 2937 35